About dostarlimab
PD-1 immune checkpoint inhibitor
Used for
- Treats certain endometrial cancers, including advanced or recurrent disease.
- Treats certain mismatch repair-deficient solid tumors that have progressed after prior treatment.
Usual adult dose
500 mg intravenously every 3 weeks for 4 doses, then 1,000 mg every 6 weeks.
Common side effects
- Fatigue
- Nausea or diarrhea
- Rash or itching
- Thyroid problems
Important warnings
- Can cause serious immune-related inflammation affecting organs such as lungs, bowel, liver, or kidneys.
- Infusion reactions can occur; treatment may need to be stopped.
- Monitor for immune effects during treatment and after it ends.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 4 months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for 4 months after the last dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.